Cargando…
CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma
Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain tumor in adults. Current treatment options typically consist of surgery followed by chemotherapy or more frequently radiotherapy, however, median patient survival remains at just over 1 year. Therefore, the need...
Autores principales: | Maggs, Luke, Cattaneo, Giulia, Dal, Ali Emre, Moghaddam, Ali Sanjari, Ferrone, Soldano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185049/ https://www.ncbi.nlm.nih.gov/pubmed/34113233 http://dx.doi.org/10.3389/fnins.2021.662064 |
Ejemplares similares
-
B7-H3-targeted CAR T cell activity is enhanced by radiotherapy in solid cancers
por: Ventin, Marco, et al.
Publicado: (2023) -
Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and tumor microenvironment, overcoming multiple obstacles of CAR T therapy for solid tumors
por: Wang, Yufeng, et al.
Publicado: (2023) -
Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment
por: Wang, Yufeng, et al.
Publicado: (2023) -
CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
por: Burger, Michael C., et al.
Publicado: (2019) -
Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature
por: Sabbatino, Francesco, et al.
Publicado: (2018)